Charles Schwab Portfolio holdings
Charles Schwab Corporation, founded in 1971 by Charles R. Schwab and headquartered in Westlake, Texas, is a leading financial services firm that revolutionized retail investing by offering low-cost brokerage services. Initially disrupting the industry with discount commissions, it has grown into a powerhouse providing a wide array of services, including trading platforms, robo-advisors, retirement accounts, and banking products, managing hundreds of billions in client assets. Known for its user-friendly technology and customer-centric approach, Schwab caters to individual investors, financial advisors, and institutions, notably expanding through its 2020 acquisition of TD Ameritrade. With a mission to democratize investing, Charles Schwab remains a dominant force in the shift toward accessible, self-directed wealth management.
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
ConocoPhillips
COP
|
+$3.16B |
| 2 |
Merck
MRK
|
+$2.72B |
| 3 |
SLB Ltd
SLB
|
+$1.62B |
| 4 |
Target
TGT
|
+$1.6B |
| 5 |
General Mills
GIS
|
+$930M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Pfizer
PFE
|
+$2.81B |
| 2 |
Blackrock
BLK
|
+$2.57B |
| 3 |
US Bancorp
USB
|
+$1.84B |
| 4 |
M&T Bank
MTB
|
+$808M |
| 5 |
Huntington Bancshares
HBAN
|
+$595M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Technology | 21.45% |
| 2 | Financials | 11.9% |
| 3 | Healthcare | 10.6% |
| 4 | Consumer Discretionary | 9.01% |
| 5 | Industrials | 8.16% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
3376
Genelux
GNLX
$134M
| $67.5K | ﹤0.01% |
+25,000
| New | +$93.8K |
|
3377
Drilling Tools International
DTI
$84.3M
| $67K | ﹤0.01% |
28,283
| – | – |
|
3378
CAMP4 Therapeutics
CAMP
$219M
| $66.7K | ﹤0.01% |
16,685
| – | – |
|
3379
Rezolute
RZLT
$473M
| $66K | ﹤0.01% |
22,757
| – | – |
|
|
UHG
3380
DELISTED
United Homes Group
UHG
| $65.5K | ﹤0.01% |
23,396
+6,000
| +34% | +$23.2K |
|
3381
Upland Software
UPLD
$13.1M
| $65.1K | ﹤0.01% |
2,278
-2
| -0.1% | -$76 |
|
3382
Coya Therapeutics
COYA
$104M
| $64.7K | ﹤0.01% |
+10,000
| New | +$63.3K |
|
3383
Protara Therapeutics
TARA
$223M
| $63.9K | ﹤0.01% |
+15,000
| New | +$67K |
|
3384
FibroBiologics
FBLG
$5M
| $62.8K | ﹤0.01% |
3,490
+3
| +0.1% | +$86 |
|
|
LFT
3385
Lument Finance Trust
LFT
$35.9M
| $62.7K | ﹤0.01% |
24,035
| – | – |
|
|
VXRT
3386
DELISTED
Vaxart
VXRT
| $62.5K | ﹤0.01% |
153,547
| – | – |
|
|
RPT
3387
Rithm Property Trust
RPT
$95.1M
| $62.2K | ﹤0.01% |
+3,611
| New | +$65.3K |
|
3388
CuriosityStream
CURI
$156M
| $61.8K | ﹤0.01% |
23,041
| – | – |
|
|
BOLD
3389
Boundless Bio
BOLD
$57.8M
| $61.1K | ﹤0.01% |
40,458
| – | – |
|
3390
VistaGen Therapeutics
VTGN
$12.3M
| $58.3K | ﹤0.01% |
23,302
| – | – |
|
3391
PepGen
PEPG
$130M
| $56.3K | ﹤0.01% |
40,070
-8,281
| -17% | -$17.1K |
|
3392
Harvard Bioscience
HBIO
$28.5M
| $56K | ﹤0.01% |
9,888
-14,082
| -59% | -$180K |
|
|
GAN
3393
DELISTED
GAN Ltd
GAN
| $55.7K | ﹤0.01% |
31,476
| – | – |
|
3394
Neuronetics
STIM
$160M
| $55.2K | ﹤0.01% |
+15,000
| New | +$54.8K |
|
3395
TriSalus Life Sciences
TLSI
$292M
| $55.2K | ﹤0.01% |
+10,000
| New | +$53.2K |
|
3396
Tevogen Inc. Common Stock
TVGN
$29.6M
| $53.6K | ﹤0.01% |
993
+1
| +0.1% | +$66 |
|
|
WW
3397
DELISTED
WW International
WW
| $52K | ﹤0.01% |
99,577
| – | – |
|
3398
Aclaris Therapeutics
ACRS
$772M
| $50.6K | ﹤0.01% |
33,079
| – | – |
|
3399
DiaMedica Therapeutics
DMAC
$351M
| $50.2K | ﹤0.01% |
13,253
+2
| +0% | +$11 |
|
3400
Atomera
ATOM
$219M
| $50K | ﹤0.01% |
12,489
+1
| +0% | +$8 |
|
Similar funds
Charles Schwab's Q1 2025 Portfolio in Review
As of Q1 2025, Charles Schwab held 3,548 positions worth $533B, down 1.7% from $542B the previous quarter. Its ten largest holdings account for 20% of the portfolio.
Trading was light in Q1 2025: portfolio turnover was 3.6%. Charles Schwab opened 55 new positions and exited 74, leaving the 3,548-position portfolio largely intact.
By sector, the portfolio is most concentrated in Technology at 21% of assets, down from 24% a quarter earlier, followed by Financials and Healthcare.
- Charles Schwab's largest Q1 2025 buy was iShares Currency Hedged MSCI Eurozone ETF: 7,259,426 shares worth $283M.
- Charles Schwab added most to ConocoPhillips in Q1 2025, an estimated $3.16B increase.
- Charles Schwab's biggest Q1 2025 reduction was Pfizer, cutting an estimated $2.81B.
- Charles Schwab fully exited Brookfield in Q1 2025, selling an estimated $218M.
- Charles Schwab's ten largest holdings make up 20% of its $533B portfolio in Q1 2025.
- Charles Schwab opened 55 new positions and closed 74 in Q1 2025.
- Charles Schwab's portfolio value fell 1.7% quarter-over-quarter to $533B.
Based on Charles Schwab's 13F filing for Q1 2025, filed 9 May 2025.